

PharmLabs San Diego Certificate of Analysis



Sample MET - JER - 2G - 3011 - 25

| | |
|---|-----------------------|
| Sample ID SD251117-020 (127783) | Matrix Isolate |
| Tested for A8 Industries | |
| Sampled - | Received Nov 17, 2025 |
| Analyses executed 4AD, AMU, TRY, PSY, SDR | Reported Nov 18, 2025 |

Laboratory note: No formulation disclosure was provided for this particular sample. Under the current method, chromatographic interference with N-methyl Tryptamine (NMT) and 4-Hydroxy-MET (4-HO-MET) prevents definitive identification of the compound present.

4AD - 4AD Tryptamines

Analyzed Nov 18, 2025 | Instrument HPLC VWD | Method SOP-4AD
 The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte | LOD ppm | LOQ ppm | Result % | Result mg/g |
|------------------------------|---------|---------|--------------|---------------|
| Mescaline (MESCL) | 0.19 | 0.584 | ND | ND |
| N-methyl Tryptamine (NMT) | 0.004 | 0.013 | ND | ND |
| 4-Hydroxy-MET (4-HO-MET) | 0.013 | 0.04 | 67.99 | 679.92 |
| n,n Dimethyltryptamine (DMT) | 0.015 | 0.048 | ND | ND |
| Psilocetin (PSLA) | 0.015 | 0.044 | ND | ND |
| 4-Hydroxy-DET (4-HO-DET) | 0.014 | 0.042 | ND | ND |
| 4-Acetoxy-MET (4-AcO-MET) | 0.018 | 0.053 | ND | ND |
| 4-Acetoxy-DET (4-AcO-DET) | 0.004 | 0.011 | ND | ND |
| 4-Bromo-DMP (2C-B) | 0.19 | 0.576 | ND | ND |
| Total Analyzed | - | - | 67.99 | 679.92 |

AMU - Amanita Muscaria

Analyzed Nov 15, 2025 | Instrument HPLC VWD | Method SOP-039 AMU
 The expanded Uncertainty of the Amanita Muscaria analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte | LOD ppm | LOQ ppm | Result % | Result mg/g |
|----------------------|---------|---------|----------|-------------|
| Ibotenic Acid (IBOA) | 1.025 | 3.105 | ND | ND |
| Muscimol (MUOL) | 0.19 | 0.576 | ND | ND |

TRY - Tryptamine

Analyzed Nov 15, 2025 | Instrument HPLC VWD | Method SOP-TRY
 The expanded Uncertainty of the Tryptamine analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte | LOD ppm | LOQ ppm | Result % | Result mg/g |
|----------------------|---------|---------|----------|-------------|
| Norbaeocystin (NORB) | 0.01 | 0.029 | ND | ND |
| Baeocystin (BAEO) | 0.01 | 0.029 | ND | ND |
| Aeruginascin (AERU) | 0.007 | 0.022 | ND | ND |
| Norpsilocin (NORP) | 0.003 | 0.009 | ND | ND |

PSY - Psilocybin & Psilocin

Analyzed Nov 15, 2025 | Instrument HPLC VWD | Method SOP-PSY
 The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ±7.81% at the 95% Confidence Level

| Analyte | LOD ppm | LOQ ppm | Result % | Result mg/g |
|-------------------|---------|---------|----------|-------------|
| Psilocybin (PSCY) | 0.007 | 0.019 | ND | ND |
| Psilocin (PSCI) | 0.003 | 0.009 | ND | ND |

UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DEA license: RP0611043
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
 Tue, 18 Nov 2025 16:22:33 -0800

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2019 Form 981. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.